



Signatory Name: Ferring Pharmaceuticals Pty Ltd

The question numbers in this report refer to the numbers in the report template. Not all questions are displayed in this report.

Status: Complete

The content in this APC Annual Report is hereby endorsed by the Chief Executive Officer, or equivalent officer of the organisation.

☒ Yes

5. Industry sector (please select 1 only):

- ☒ Brand Owner / Wholesaler / Retailer
- ☐ Packaging Manufacturer
- ☐ Waste Management
- ☐ Other - Commercial Organisation
- ☐ Community Group
- ☐ Industry Association
- ☐ Government
- ☐ Raw Material Supplier
- ☐ Other:

6. Industry type (please select 1 only):

- ☐ Food & Beverage
- ☒ Pharmaceutical / Personal Care / Medical
- ☐ Hardware
- ☐ Homewares
- ☐ Communications / Electronics
- ☐ Clothing / Footwear / Fashion
- ☐ Chemicals / Agriculture
- ☐ Fuel
- ☐ Large Retailer
- ☐ Tobacco
- ☐ Shipping Company
- ☐ Airline
- ☐ Other:

7. Please indicate your organisation's reporting period:

- ☒ Financial Year: 1 July 2015 – 30 June 2016
- ☐ Calendar Year: 1 January 2016 – 31 December 2016

Goal 1: Design

KPI 1: % of signatories with documented policies and procedures for evaluating and procuring packaging using the SPGs or equivalent.

9. Does your company have documented policies and procedures for evaluating and procuring packaging using the SPGs or equivalent?



Yes



No

10. Of the types of packaging **existing at the beginning of the reporting period**, what percentage had been reviewed using the Sustainable Packaging Guidelines (SPG) by the end of the reporting period?

85 %

11. Have any new types of packaging been introduced during the reporting period?



Yes



No

12. If yes, of the **new types of packaging introduced during the reporting period**, what percentage have been reviewed using the Sustainable Packaging Guidelines (SPG) by the end of the reporting

%

13. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 1

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Establish a documented policy and procedure for evaluating packaging using the SPG assessment process. Establish a documented policy and procedure for evaluating packaging using the SPG assessment process.	<p>Locally, we do not have a formal procurement policy as we do not procure packaging materials and we are therefore reliant on the packaging developments and related policies and procedures that our Head Office have put in place for a world-wide market.</p> <p>Therefore, Australia will be a recipient of these policies and procedures which must adhere to the various medical and therapeutic goods governing bodies around the world.</p> <p>That said, we do:</p> <ul style="list-style-type: none">Engage with our Head Office and third party logistics provider, as the two main organisations in our product supply chain, to ensure that they are aware of our Australian Packaging Covenant (APC) reporting obligations.Circulate to them a range of questions, requiring responses, to assist us with the implementation of our local Sustainable Packaging Guidelines (SPG) assessment process. <p>We will revisit the requirements for a local policy when the details of the new Australian Packaging Covenant are released in the early part of 2017.</p>
2.	Establish and maintain a centralised database containing all documentation and other information relating to the APC obligations including results from the SPG assessments.	Any information related to our communications with relevant parties at our Head Office regarding the SPG assessments of our packaging continues to be held in a secure, cloud based tool. This allows all relevant parties involved in contributing to these SPG assessments access to the information in a single file.

3.	Review packaging for existing products using the SPG assessment process.	<p>Five SPG assessments have been conducted covering over 85% of packaging placed on the Australian market.</p> <p>These assessments have involved input from our Head Office and we continue to engage with them over specific SPG matters, as well as our broader APC obligations.</p>
4.	Document and report any actual or attempted changes to packaging identified as part of reviews.	<p>Globally, Ferring has a number of programs in place aimed at reducing the impact of packaging for its world-wide market, including:</p> <ul style="list-style-type: none"> • Ferring Spain has reduced the carton weight of its packaging by 43% between 2013-14, the equivalent to 1.6 tonnes of carton weight per year. • In Switzerland, there has been a reduction in the weight of secondary packaging of key medicines by 10%. <p>In previous years, Ferring Pharmaceuticals Australia worked with our Head Office to improve the presentation of a major product which included supplying disposables separate from the drug. This resulted in a substantial reduction in wastage of disposables.</p>

14. Describe any constraints or opportunities that affected performance under this KPI

We have conducted five SPG assessments to date representing some 85% of the different packaging forms that are imported into Australia.

We use a cloud based information management system that enables us to carry out our SPG assessments in a systematic approach, retaining all information from these assessments in a single, secure, online environment.

Our ability to influence packaging changes is very limited as Australia represents a small proportion of the overall sales of products into a world-wide market. That said we are very aware of our signatory obligations and communicate these to our Head Office to ensure that they are aware of our requirements and determine if any of the SPG requirements may be used as input to the packaging design carried out by the Head Office.

Goal 2: Recycling

KPI 3: % signatories applying on-site recovery systems for used packaging.

15. Do you have on-site recovery systems for recycling used packaging?

- ☒ Yes at all facilities/ sites
- ☐ Yes at some, but not all facilities/ sites
- ☐ No

16. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 3

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Document baseline information for office waste and recycling and report on annual progress.	<p>We run an office based operation from rented space. Therefore we work with our property manager to recycle all paper, plastics and ink cartridges.</p> <p>As our waste and recycling is managed by a third party, we are unable to document the actual level of recycling achieved from our efforts.</p> <p>However, all staff are made aware of the importance of placing items in the recycling stream rather than sending things to landfill unnecessarily.</p>

2.	Determine the onsite waste and recycling procedures of our 3rd party logistics provider, including the reuse of secondary and tertiary packaging as protective packaging for goods outwards.	<p>Ferring Pharmaceuticals engages a third party logistics provider to manage the storage and distribution of products imported into Australia. This is done from the service provider's national Distribution Centre in NSW, which is a state-of-the-art facility specifically designed and built for the broader healthcare industry.</p> <p>A quality management system is in place at this site that meets the internationally recognised Good Manufacturing Practice (GMP) Standard.</p> <p>This includes ensuring a clean environment, which means proactive waste and recycling practices are in place that meet TGA requirements.</p> <p>We have sent a set of questions to our 3PL seeking further clarification on their waste and recycling practices and await to hear back from them.</p>
----	--	--

17. Describe any constraints or opportunities that affected performance under this KPI

Our main operations are from serviced offices, where our staff are encouraged to use the recycling facilities available for paper, plastics and cartridges as part of our APC signatory obligations.

Ferring Pharmaceuticals engages the services of a third party logistics (3PL) provider which receives our imported products, which are fully packaged when they arrive at their facility, for distribution across Australia.

This 3PL is recognised for its work with some of the world's best known brands across the pharmaceuticals, biotechnology and medical equipment industries, that operates from a purpose-designed distribution facility which must comply with the requirements of the Therapeutic Goods Act (TGA).

We have requested responses from our 3PL to a number of questions related to this particular KPI and await their response.

KPI 4: Signatories implement formal policy of buying products made from recycled packaging.

18. Does your company have a formal policy of buying products made from recycled packaging?

☐ Yes ☒ No

Please explain why not

As Ferring Pharmaceuticals' products are 100% packaged before they arrive in Australia, we are following up with our Head Office contact in regard to references made to 'green purchasing policies' in the latest Ferring Group CSR report.

While we have no input to the packaging design process for products that are sold into a world market, we have asked our Third Party Logistics provider, which purchases secondary cartons within Australia on our behalf, if these cartons have any recycled content.

We are aware that we can influence purchasing practices within our Australian office. However, we have had disappointing outcomes to date in using paper (our major consumable) with recycled content due to it adversely affecting our photocopiers, so we are not considering this option further at the moment.

19. Is this policy actively used?

☐ Yes ☒ No

20. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 4

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Examine the possibility of introducing a Buy Recycled policy.	<p>In Australia, we are reliant on the work of our Head Office to progress the matter of purchasing consumables and packaging with recycled content as we are a small, office based operation.</p> <p>We are aware, from the latest Group CSR Report, that the Head Office is trying to integrate environmental considerations into green purchasing policies and we continue to seek definitive advice on this matter.</p> <p>Locally, our major consumable where we could have the biggest impact is in the purchase of office paper with recycled content.</p> <p>To date, however, we have had disappointing results from purchasing this paper, as it has had adverse impact on the office copiers.</p>
2.	Identify opportunities for improvements in Buy Recycled quantities.	<p>Primary packaging that comes into contact with medicine cannot contain recycled materials due to world-wide pharmaceutical regulations.</p> <p>However, Head Office responses to a Sustainable Packaging Guidelines assessment identified that the secondary shipper boxes consisted of corrugated cardboard (Kraft) with 54 % recycled material.</p> <p>While our 3PL manages a number of clients from the one facility, we have asked our provider, which purchases secondary cartons within Australia on behalf of its customers, if these cartons have any recycled content and await their reply.</p>

21. Describe any constraints or opportunities that affected performance under this KPI

Regulations restrict the source of the primary packaging that is placed against pharmaceutical products, requiring that it must be new packaging, with no recycled content. The quality of packaging required to receive laser-printed information, again in response to regulatory requirements, does not allow for recycled content.

There is an opportunity for Ferring Pharmaceuticals to engage with our global operations to determine if there is an element of recycled material in the outer and secondary packaging. On previously reviewed products this can be in excess of 54% recycled materials for this packaging.

We await a response from our 3PL as to whether or not there is any recycled content in the secondary cartons which it purchases on our behalf to transport our goods within Australia.

Goal 3: Product Stewardship

KPI 6: % signatories with formal processes to work collaboratively on packaging design and / or recycling.

22. Does your company have formal processes in place for collaborating with other companies or organisations on improved packaging designs and/or recycling which aims to reduce or eliminate waste?



Yes



No

Provide details of policies and procedures (including names of policies/ procedures)

We have engaged with the Environment, Health and Safety Department at our Head Office in Switzerland over the last six years in regard to the SPGs that we have conducted to date, as well as informing them of our broader APC obligations.

The other important company in our supply chain is the 3rd Party Logistics provider which we engage to manage the products imported into Australia for eventual distribution throughout the country. Therefore we have a strong contractual relationship with this company to ensure our customers receive their orders in a timely manner.

23. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 6

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Engage with our 3rd party logistics provider in regard to APC related information, where available, about their warehouse operations, including packaging purchases, waste and recycling practices.	<p>We have a formal contract in place with our 3PL which delivers our products and products from other pharmaceutical, biotechnology and medical equipment companies from purpose designed distribution facilities.</p> <p>While we don't have direct influence over their operations, we have informed them of our APC obligations and are awaiting information around their waste and recycling systems at the facility, as well as the purchasing policies of secondary and tertiary packaging bought on behalf of their customers using that facility.</p>
2.	Liaise with the global arm of our business to identify international sustainability initiatives that impact on local operations and inform them of our APC obligations.	<p>Our Scientific Affairs department continues to engage with the Environment, Health and Safety Department at our Head Office in Switzerland regarding our SPG and APC obligations.</p> <p>As well, we try and identify how global sustainability initiatives may impact our local operations and are aware of a number of packaging and resource management initiatives included in the 2014 Ferring Group Corporate Social Responsibility Review.</p>

24. Describe any constraints or opportunities that affected performance under this KPI

We will continue to engage with our Head Office Environment, Health and Safety Department to find out how global sustainability initiatives may impact on our local operations, while providing input to Ferring's global CSR program based on meeting our APC obligations.

KPI 7: % signatories showing other Product Stewardship outcomes.

25. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 7

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Participate in the roll out of Ferring Pharmaceuticals' global Corporate Social Responsibility (CSR) program.	<p>The Australian operations will benefit from the environmental issues that the global business is addressing through activities such as:</p> <ul style="list-style-type: none"> • Quality by Design and Lean Six Sigma, • green purchasing policies, • sustainable manufacturing practices, and • training and education. <p>All Ferring affiliates are actively encouraged to engage in environmental activities specific to their local markets/operations and this is where our involvement in the APC can contribute.</p>
2.	Maintain ISO 14001 certification and environmental management system across all applicable manufacturing sites.	<p>The Ferring Group is progressively implementing internationally recognised management systems to ensure that its programs are sustainable and effective.</p> <p>ISO14001/ OHSAS18001 standards are being followed at all our manufacturing sites with certification by accredited registrars.</p>
3.	Engage in other product stewardship outcomes.	<p>Ferring Pharmaceuticals in Switzerland has provided key logistical support for the first expedition of the Swiss Polar Institute (SPI). This new interdisciplinary centre will be devoted to researching the Earth's poles and other extreme environments.</p> <p>The purpose of this first expedition is to measure and quantify the impact of climate change and pollution in the Southern Ocean.</p> <p>Locally, Ferring Pharmaceuticals has provided unrestricted research and education grants in the areas of Gastroenterology, Reproductive Health, Urology and Prostate Cancer to advance science and improve education and clinical practice in these therapeutic areas to improve outcomes for patients.</p>

26. Since the beginning of the reporting period, has your company had any other outcomes related to product stewardship?

☒ Yes ☐ No

If yes, please give examples of other product stewardship outcomes

In April this year, the Ferring Group announced that it was providing logistical support to the Swiss Polar Institute's first major project called the Antarctic Circumnavigation Expedition (ACE). ACE will be the first scientific expedition to fully sail around the southernmost continent, comprising 55 researchers from 30 countries. This team is working on 22 research projects covering a spectrum of topics, including the composition of plankton, threatened animal species, the presence of microplastics in the surrounding water, the carbon cycle, micro-organisms that flourish in the ocean depths or in ice, and the impact of waves on the coasts.

Locally, Ferring Pharmaceuticals has supported the following organisations through the FY15-16:

- Continence Foundation of Australia,
- Crohn's and Colitis Association,
- Australian Pituitary Foundation and
- Access Australia.

27. Describe any constraints or opportunities that affected performance under this KPI

In its 2014 CSR review, Ferring Group Head Office identified the importance of improving the environmental footprint of the organisation's activities throughout its full supply chain, from the sourcing of materials to the manufacture, supply and distribution of its medicines. This includes consideration of water and energy use.

The Community Pillar of the Group's CSR review identified some 33 different projects from around the world that different parts of the organisation were involved in. Activities that are either:

- Relevant to Ferring's areas of expertise (e.g. health, education) that enable access to, advice on treatment or care; or
- Focused on what local Ferring representatives believe are important and relevant to the communities in which they operate around our manufacturing and operational sites.

Locally, Ferring Pharmaceuticals has provided unrestricted research and education grants in the areas of Gastroenterology, Reproductive Health, Urology and Prostate Cancer.

KPI 8: Reductions in packaging items in the litter stream.

28. Please indicate your progress this year towards achieving your annual targets and milestones for KPI 8

	Target: According to your Action Plan, what did you set out to do?	Actual: What did you achieve?
1.	Add appropriate recycling and litter management information on all primary and secondary packaging.	<p>Our local Scientific Affairs department is working on the addition of recycling logos to our packaging to inform consumers on the proper disposal of our packaging.</p> <p>While TGA does not have specific guidance on this issue, Australian Consumer Law requires that logos applied to packaging are substantiated. As such, we will follow the guidance outlined in the publication "Green Marketing and the Australian Consumer Law" for this project.</p> <p>Ferring Pharmaceuticals has also, where possible and allowable, reduced the potential for consumer litter by replacing paper inserts containing consumer medicine information and directing consumers to access the same information online, or, as appropriate, via the community pharmacy.</p>

2.	Determine the onsite litter management practices of our 3rd party logistics provider.	<p>We have sought information from our third party logistics provider regarding their litter management practices and procedures and await their response.</p> <p>However, as a result of regular site visits, Ferring Pharmaceuticals has determined that our 3rd party logistics provider, operating from a state of the art facility, ensures that proper OH&S requirements are in place.</p> <p>This results in broader good business practices ensuring that no materials are left lying around that could become a litter hazard.</p>
3.	Manage litter in office and staff break areas.	All onsite waste at our serviced offices continues to be segregated into the appropriate recycling and waste streams (paper and used printer cartridges), thus minimising any propensity for litter in the offices.

29. Describe any constraints or opportunities that affected performance under this KPI

Our local Scientific Affairs department is currently looking into how we can improve consumer information about the proper disposal of our packaging.

This includes examining any TGA specific requirements which would apply to the inclusion of such information, as well as applying any logos or wording to the packaging in accordance with the publication "Green Marketing and the Australian Consumer Law".

Office staff are encouraged to make use of the waste and recycling facilities as part of our response to our APC signatory obligations which results in the minimisation of any litter in the office and staff break areas.

Your Experiences

This section lets you share with us any achievements, good news stories and areas of difficulties in making progress against your plan and the Covenant goals and KPIs.

30. Key achievements or good news stories

We submitted a revised Action Plan to the APC updating them, and our associated stakeholders, as to how Ferring Pharmaceuticals has progressed in meeting the Covenant's goals and what further actions we aim to implement during the APC extension period through to June 2017.

This should also help us respond to the next five year Australian Packaging Covenant, the details of which, related to member obligations, are due to be announced at the beginning of 2017.

Ferring Pharmaceuticals uses a secure, cloud based, database tool for authorised staff to manage our information requirements, not only for our broader APC obligations, but updating any SPG information related to our packaging.

Ferring Pharmaceuticals engages the services of a third party logistics (3PL) to distribute our products around Australia. This 3PL is recognised for its work with some of the world's best known brands across the pharmaceuticals, biotechnology and medical equipment industries, that operates from a purpose-designed distribution facility which must comply with the requirements of the Therapeutic Goods Act (TGA).

At Ferring Pharmaceuticals we understand that our primary responsibility is the delivery of therapies that improve the health and well-being of patients. We also understand that we have a broader societal responsibility to do this in a way that maximises the positive, and minimises the negative impacts we have on the communities and the environment in which we operate. This is what our stakeholders expect of us and it is what we expect of ourselves.

Therefore, locally, we are proud of our continued provision of unrestricted research and education grants in our therapeutic areas of focus including Gastroenterology, Reproductive Health, Urology and Prostate Cancer.

31. Areas of difficulties in making progress against your plan, Covenant goals or KPIs